ATE549016T1 - Pharmazeutische zusammensetzungen mit verbesserten auflöseprofilen für schwerlösliche wirkstoffe - Google Patents

Pharmazeutische zusammensetzungen mit verbesserten auflöseprofilen für schwerlösliche wirkstoffe

Info

Publication number
ATE549016T1
ATE549016T1 AT06740898T AT06740898T ATE549016T1 AT E549016 T1 ATE549016 T1 AT E549016T1 AT 06740898 T AT06740898 T AT 06740898T AT 06740898 T AT06740898 T AT 06740898T AT E549016 T1 ATE549016 T1 AT E549016T1
Authority
AT
Austria
Prior art keywords
pharmaceutical compositions
active ingredients
dissolution profiles
poorly soluble
soluble active
Prior art date
Application number
AT06740898T
Other languages
English (en)
Inventor
Huailiang Wu
Geoff Zhang
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Application granted granted Critical
Publication of ATE549016T1 publication Critical patent/ATE549016T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
AT06740898T 2005-04-11 2006-04-11 Pharmazeutische zusammensetzungen mit verbesserten auflöseprofilen für schwerlösliche wirkstoffe ATE549016T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67020705P 2005-04-11 2005-04-11
PCT/US2006/013651 WO2006110815A1 (en) 2005-04-11 2006-04-11 Pharmaceutical compositions having improved dissolution profiles for poorly soluble drugs

Publications (1)

Publication Number Publication Date
ATE549016T1 true ATE549016T1 (de) 2012-03-15

Family

ID=36648686

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06740898T ATE549016T1 (de) 2005-04-11 2006-04-11 Pharmazeutische zusammensetzungen mit verbesserten auflöseprofilen für schwerlösliche wirkstoffe

Country Status (16)

Country Link
US (4) US20060228411A1 (de)
EP (2) EP2286800A1 (de)
JP (2) JP5284777B2 (de)
AT (1) ATE549016T1 (de)
CA (1) CA2603783C (de)
CY (1) CY1112980T1 (de)
DK (1) DK1868581T3 (de)
ES (1) ES2384333T3 (de)
HR (1) HRP20120502T1 (de)
ME (1) ME02003B (de)
MX (1) MX2007012642A (de)
PL (1) PL1868581T3 (de)
PT (1) PT1868581E (de)
RS (1) RS52354B (de)
SI (1) SI1868581T1 (de)
WO (1) WO2006110815A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110091504A (ko) * 2008-09-24 2011-08-11 립-엑스 파마슈티칼즈, 인크. 퀴놀론 화합물의 제조 방법
BRPI0921049A2 (pt) * 2008-11-14 2017-03-28 Portola Pharm Inc composição sólida para liberação controlada de agentes ativos ionizáveis com solubilidade aquosa pobre a um ph baixo e métodos para uso da mesma
MY188453A (en) * 2008-11-15 2021-12-09 Melinta Subsidiary Corp Antimicrobial compositions
US20130165459A1 (en) * 2010-01-12 2013-06-27 Norvartis Pharma Ag Pharmaceutical composition and dosage forms of elinogrel and methods of use thereof
HUE026794T2 (en) * 2010-09-30 2016-07-28 Toyama Chemical Co Ltd The oleum salt of 6-fluoro-3-hydroxy-2-pyrazinecarboxamide
CN104098548B (zh) * 2013-04-11 2017-07-18 上海医药工业研究院 一种Delafloxacin的精制方法
TWI705814B (zh) 2014-06-20 2020-10-01 美商梅琳塔有限責任公司 醫藥組成物及其用途
TW201605447A (zh) * 2014-06-20 2016-02-16 美林塔治療學有限公司 處理感染的方法
UY36402A (es) 2014-11-14 2016-06-30 Melinta Therapeutics Inc Método para tratar, prevenir, o reducir el riesgo de infección cutánea

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5221575B2 (de) * 1972-03-18 1977-06-11
DE2213275C3 (de) * 1972-03-18 1979-11-15 Desitin-Werk, Carl Klinke Gmbh, 2000 Hamburg Verfahren zur Herstellung von 5,5-Diphenylhydantoin-Natrium-Lösungen als Infusionskonzentrate
FR2525108B1 (fr) * 1982-04-19 1989-05-12 Elan Corp Ltd Medicaments a haut degre de solubilite et procede pour leur obtention
DE3420743A1 (de) * 1984-06-04 1985-12-05 Bayer Ag, 5090 Leverkusen 7-amino-1-cyclopropyl-6,8-dihalogen-1,4-dihydro-4-oxo-3-chinolincarbonsaeuren, verfahren zu ihrer herstellung sowie diese enthaltende antibakterielle mittel
US4696814A (en) * 1985-08-21 1987-09-29 Warner-Lambert Company Parenteral phenytoin compositions
IT1207994B (it) * 1986-01-03 1989-06-01 Therapicon Srl Sali idrosulubili di composti adattivita' antiinfiammatoria ed analgesica, loro preparazione ed utilizzo in composizioni farmaceutiche.
DE3626868A1 (de) * 1986-08-08 1988-02-11 Bayer Ag Parenterale loesung
AU6001790A (en) * 1989-08-02 1991-02-07 Warner-Lambert Company Formulations of phenytoin sodium for intravenous administration
JP2613139B2 (ja) * 1990-07-19 1997-05-21 エスエス製薬 株式会社 キノロンカルボン酸誘導体
GB9121316D0 (en) * 1991-10-09 1991-11-20 Wellcome Found Heterocyclic compounds
ES2160582T3 (es) * 1992-04-03 2001-11-16 Nippon Kayaku Kk Capsula dura de ocfosfato de citarabina.
JPH09511516A (ja) * 1994-04-12 1997-11-18 カイロサイエンス・リミテッド グルカミン誘導体を用いるエトドラックの分割法
TW487582B (en) * 1995-08-11 2002-05-21 Nissan Chemical Ind Ltd Method for converting sparingly water-soluble medical substance to amorphous state
JP3103380B2 (ja) * 1995-09-22 2000-10-30 湧永製薬株式会社 新規ピリドンカルボン酸誘導体又はその塩並びに該物質を有効成分とする抗菌剤
DE59804823D1 (de) * 1997-09-25 2002-08-22 Bayer Ag Arzneimittelformulierung mit kontrollierter wirkstofffreisetzung
EP1219618A4 (de) * 1999-09-02 2002-09-18 Wakunaga Pharma Co Ltd Qunolin-carbonsäure-derivate oder ihre salze
EP1175205B1 (de) * 1999-11-12 2006-06-14 Abbott Laboratories Feste dispersion mit ritonavir, fenofibrat oder griseofulvin
GB9929037D0 (en) * 1999-12-08 2000-02-02 Glaxo Wellcome Spa Heterocyclic derivatives
DE10031043A1 (de) * 2000-06-26 2002-02-14 Bayer Ag Retardzubereitungen von Chinolonantibiotika und Verfahren zu ihrer Herstellung
JP4290381B2 (ja) * 2002-04-11 2009-07-01 学校法人 聖マリアンナ医科大学 ピリドンカルボン酸化合物含有エマルション
US20040248942A1 (en) * 2003-02-20 2004-12-09 Bonnie Hepburn Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
DK1459739T3 (da) * 2003-03-19 2008-05-19 Jordanian Pharmaceutical Mfg Ikke-hydroskopiske farmaceutiske sammensætninger indeholdende ikke-hydratiserede quinolin-carboxylsyrer
US20050085446A1 (en) * 2003-04-14 2005-04-21 Babu M.K. M. Fluoroquinolone formulations and methods of making and using the same
JP2005008625A (ja) * 2003-05-23 2005-01-13 Santen Pharmaceut Co Ltd キノロン系抗菌化合物を含有する点眼液
DK3056492T3 (da) * 2004-10-08 2021-12-13 Abbvie Inc Megluminsalt og krystallinke former deraf af et lægemiddel (delafloxacin)

Also Published As

Publication number Publication date
US20060228411A1 (en) 2006-10-12
EP1868581B1 (de) 2012-03-14
CA2603783A1 (en) 2006-10-19
PT1868581E (pt) 2012-06-22
RS52354B (en) 2012-12-31
US20150057266A1 (en) 2015-02-26
PL1868581T3 (pl) 2012-08-31
HRP20120502T1 (hr) 2012-07-31
EP1868581A1 (de) 2007-12-26
US20120309740A1 (en) 2012-12-06
CA2603783C (en) 2014-11-18
ME02003B (me) 2012-12-31
DK1868581T3 (da) 2012-07-09
JP2013121976A (ja) 2013-06-20
EP2286800A1 (de) 2011-02-23
CY1112980T1 (el) 2016-04-13
WO2006110815A1 (en) 2006-10-19
JP2008535925A (ja) 2008-09-04
US20100324018A1 (en) 2010-12-23
JP5284777B2 (ja) 2013-09-11
SI1868581T1 (sl) 2012-06-29
ES2384333T3 (es) 2012-07-03
MX2007012642A (es) 2008-01-11

Similar Documents

Publication Publication Date Title
ATE549016T1 (de) Pharmazeutische zusammensetzungen mit verbesserten auflöseprofilen für schwerlösliche wirkstoffe
NO20053076D0 (no) Farmasoytisk formulering med en uloselig aktiv forbindelse.
BRPI0516830A (pt) composições de droga de liberação sustentada convenientemente implantáveis
DE602004025950D1 (de) Pharmazeutische formulierung mit lanthanum-verbindungen
NO20075111L (no) Farmasoytisk sammensetning
CR9587A (es) Derivados de piridazina
ATE551989T1 (de) Kleinmolekülige heilmittelformulierung mit verzögerter freisetzung
CY1108700T1 (el) Συνθεσεις απελευθερωσης φαρμακου εστερα αλφα-υδροξυ οξεος και μεθοδοι χρησης
DE602004011398D1 (de) Direkt komprimierbare pharmazeutische zusammensetzung für die orale verabreichung von cci-779
NO20080220L (no) Formuleringer med hoy medikament belastning og doseringsformer
ATE474561T1 (de) Orodispersible pharmazeutische zusammensetzung für die orale, oromukosale oder sublinguale verabreichung von agomelatin
ITMI20050729A1 (it) Nuova formulazione biologicamente attiva
CL2007003444A1 (es) Compuestos derivados de pirrolo[3,2-c]piridina; composicion farmaceutica; y uso en el tratamiento de un trastorno hiperproliferativo o una enfermedad inflamatoria.
CR9703A (es) Derivados de pirazolona
ATE354362T1 (de) Stabilisierte pharmazeutische zusammensetzung enthaltend einen amorphen wirkstoff
ITMI20051630A1 (it) Formulazione farmaceutica sterile iniettabile contenente almeno due principi attivi
FR2881957B1 (fr) Comprimes comprenant une substance biologiquement active et un excipient
DE602005021475D1 (de) Magenresistente pharmazeutische dosierform mit n-(2-(2-phthalimidoethoxy)-acetyl)-l-alanyl-d-glutaminsäure (lk-423)
ECSP099442A (es) Derivados de heteroaril-pirrolidinil- y -piperidinil-cetona
ATE439832T1 (de) Feste pharmazeutische arzneimittelformulierung enthaltend diacerein und meloxicam
NO20064808L (no) Orale matrixformuleringer med licarbazepin
ATE415949T1 (de) Pharmazeutische formulierung mit levothyroxin- natrium
AR048672A1 (es) Tabletas de desintegracion que comprenden licarbazepina
MA28603B1 (fr) Composition pharmaceutique antimycobacterienne
CY1109541T1 (el) Φαρμακευτικη συνταγοποιηση για την θεραπεια οστεοαρθριτιδας η οποια περιεχει κλοδρονικο οξυ και υαλουρονικο οξυ